DW Healthcare Partners (DWHP), a healthcare-focused private equity firm with offices in Toronto, Ontario and Park City, Utah, has made an undisclosed investment in Med-Pharmex Inc.of Pomona, California. Med-Pharmex is focused on pharmaceutical research, formulation, and manufacturing in the animal health industry, and operates three manufacturing facilities. DWHP is currently investing its third fund, closed at $265 million in February 2013.
You are browsing the archive for DW Healthcare Partners - peHUB.
Private equity firm DW Healthcare Partners (DWHP) has promoted two investment professionals, and added five to its team. Eric Keen was promoted from vice president to principal, and works in the firm’s Toronto office. Sameer Mathur was promoted from associate to vice president, and is also based in Toronto. The new DWHP hires are: Phillip Smith, Karen Jones, Eric Moore, Alex Aptekman, and Philip Edmunds.
Drew McCartney has joined BelHealth Investment Partners’ operating committee. Recently, McCartney served as the Executive-In-Residence at DW Healthcare Partners. Port Washington, N.Y.-based BelHealth is a PE firm focused on the small-cap healthcare industry.
Eric Keen has left left the Riverside Company, where he was VP, to join DW Healthcare Partners as a VP. PRESS RELEASE: Park City, Utah, September 20, 2010 – DW Healthcare Partners (DWHP), a healthcare focused private equity firm with over $250 million in committed capital under management, today announced that Mr. Eric Keen, former Vice President with [...]
Cryo-Cell has rejected a $17.63 million takeover bid from DW Healthcare Partners. DW Healthcare has offered to buy Cryo-Cell for $1.50 a share, representing a 67% premium to the company’s Friday closing stock price. Cryo-Cell’s board has determined that the offer is “inadequate and believes that it significantly undervalues the company and its growth prospects,” according to a statement. Oldsmar, Fla.-based Cryo-Cell operates a cord blood bank services. DW Healthcare, of Park City, Utah, is a healthcare focused PE firm.